Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. 1990

G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
Repligen Corporation, Cambridge, MA 02139.

The principal neutralizing determinant (PND) of human immunodeficiency virus HIV-1 is part of a disulfide bridged loop in the third variable region of the external envelope protein, gp120. Analysis of the amino acid sequences of this domain from 245 different HIV-1 isolates revealed that the PND is less variable than thought originally. Conservation to better than 80 percent of the amino acids in 9 out of 14 positions in the central portion of the PND and the occurrence of particular oligopeptide sequences in a majority of the isolates suggest that there are constraints on PND variability. One constraining influence may be the structural motif (beta strand--type II beta turn--beta strand--alpha helix) predicted for the consensus PND sequence by a neural network approach. Isolates with a PND similar to the commonly investigated human T cell lymphoma virus IIIB (HTLV-IIIB) and LAV-1 (BRU) strains were rare, and only 14 percent of sera from 86 randomly selected HIV-1 seropositive donors contained antibodies that recognized the PND of these virus isolates. In contrast, over 65 percent of these sera reacted with peptides containing more common PND sequences. These results suggest that HIV vaccine immunogens chosen because of their similarity to the consensus PND sequence and structure are likely to induce antibodies that neutralize a majority of HIV-1 isolates.

UI MeSH Term Description Entries
D008889 Military Personnel Persons including soldiers involved with the armed forces. Air Force Personnel,Armed Forces Personnel,Army Personnel,Coast Guard,Marines,Navy Personnel,Sailors,Soldiers,Submariners,Military,Force Personnel, Air,Personnel, Air Force,Personnel, Armed Forces,Personnel, Army,Personnel, Military,Personnel, Navy,Sailor,Soldier,Submariner
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D014644 Genetic Variation Genotypic differences observed among individuals in a population. Genetic Diversity,Variation, Genetic,Diversity, Genetic,Diversities, Genetic,Genetic Diversities,Genetic Variations,Variations, Genetic
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III

Related Publications

G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
September 1991, Science (New York, N.Y.),
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
December 2005, Journal of biomolecular structure & dynamics,
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
January 1995, Journal of peptide science : an official publication of the European Peptide Society,
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
February 1999, Journal of biomolecular structure & dynamics,
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
October 1991, AIDS research and human retroviruses,
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
September 1993, Journal of acquired immune deficiency syndromes,
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
May 1992, Biochemistry,
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
January 1995, Vaccine,
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
August 2010, Nature structural & molecular biology,
G J LaRosa, and J P Davide, and K Weinhold, and J A Waterbury, and A T Profy, and J A Lewis, and A J Langlois, and G R Dreesman, and R N Boswell, and P Shadduck
October 1995, Journal of virology,
Copied contents to your clipboard!